ASSOCIATION BETWEEN HEMOSTATIC MARKERS WITH THE SEVERITY OF COVID- 19 IN MEDAN, INDONESIA
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
The Coronavirus disease of 2019 (COVID-19) has resulted in significant morbidity and mortality worldwide. Doctors may use several laboratory tests, such as the biomarkers for hemostasis alteration, to assess the severity and prognosis of COVID-19 patients. This study aims to determine the association between hemostatic markers [including prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (APTT), D-dimer, fibrinogen, platelet] and the clinical spectrum of SARS-CoV-2 infected patients (including moderate and severe COVID-19, and the non-survivors). This retrospective cohort analyzed the hospital medical records of 120 COVID-19 inpatients from January to December 2021 in Medan city, Indonesia. This study revealed a significant association between increasing values of PT/INR, APTT, fibrinogen, D-dimer, and the clinical spectrum of COVID-19 patients.
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.